Schonfeld Strategic Advisors’s Soleno Therapeutics SLNO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,964	Closed	-$4.27M	–	2545
2025 Q2	$4.27M	Buy	50,964 +15,258	+43%	+$1.14M	0.03%	616
2025 Q1	$2.55M	Buy	+35,706	New	+$1.74M	0.02%	842
2024 Q4	–	Sell	-54,273	Closed	-$2.74M	–	2353
2024 Q3	$2.74M	Buy	54,273 +254	+0.5%	+$12.2K	0.02%	758
2024 Q2	$2.2M	Buy	54,019 +8,547	+19%	+$362K	0.01%	868
2024 Q1	$1.95M	Sell	45,472 -15,418	-25%	-$697K	0.01%	1002
2023 Q4	$2.45M	Buy	60,890 +37,690	+162%	+$1.07M	0.02%	733
2023 Q3	$685K	Buy	+23,200	New	+$140K	0.01%	1132
2021 Q1	–	Sell	-1,253	Closed	-$36K	–	2097
2020 Q4	$36K	Sell	1,253 -1,374	-52%	-$39.7K	﹤0.01%	1509
2020 Q3	$98K	Buy	+2,627	New	+$76.8K	﹤0.01%	1274

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schonfeld Strategic Advisors's SLNO Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 50,964 shares — an estimated $4.27M sold.

Schonfeld Strategic Advisors first reported a position in SLNO in Q3 2020 and held it in 9 quarters. The position peaked at $4.27M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

Schonfeld Strategic Advisors reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 50,964 Soleno Therapeutics shares in Q3 2025, an estimated $4.27M.
Schonfeld Strategic Advisors first reported a position in Soleno Therapeutics in Q3 2020 and held it in 9 quarters.
Schonfeld Strategic Advisors's Soleno Therapeutics position peaked at $4.27M in Q2 2025.
240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.